Why Caris Life Sciences Is On Investors’ Radar

Caris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but showing a roughly 19% decline over the past 3 months.

The recent 10.2% 30 day share price return stands against a 19.2% 90 day decline and a 25.1% year to date share price fall, indicating fading momentum despite the latest move.

If Caris’s recent swings have you thinking about where else growth in healthcare and AI might emerge, it could be worth scanning 33 healthcare AI stocks

With Caris trading at US$20.20 against an analyst price target of US$29.69 and an estimated intrinsic discount of around 48%, you have to ask whether this is a genuine mispricing or if the market is already factoring in future growth potential.

Most Popular Narrative: 72.8% Undervalued

Talos’s widely followed narrative puts Caris Life Sciences’ fair value at $74.17 versus the last close at $20.20, a wide gap that rests on an aggressive growth and margin story.

Caris Life Sciences ($CAI) is the "Big Data" play of the biotech world. While companies like Recursion ($RXRX) use AI to find drugs, Caris uses AI to tell doctors which drug to use for a specific patient. They possess the world's largest and most comprehensive clinico-genomic database. The market currently prices CAI as a standard diagnostic lab, missing the massive optionality of its "Data-as-a-Service" business model, where pharmaceutical giants pay to access its treasure trove of patient data for drug discovery.

Curious what has to happen for that fair value to stack up? The narrative leans on rapid revenue expansion, higher margins, and a future earnings multiple more often seen in software style platforms. The exact mix of growth, profitability, and valuation expectations behind $74.17 is where the real story sits.

Result: Fair Value of $74.17 (UNDERVALUED)

However, that upside story can fray quickly if revenue growth slows or if high net losses around US$538 million persist longer than the market expects.

Next Steps

If this story of potential upside and risk feels finely balanced, it is worth reviewing the numbers yourself and deciding where you stand. To see what investors currently view as the bright spots in the thesis, check out the 3 key rewards

Looking for more investment ideas?

Do not stop at one stock. Broader ideas can help you stress test your thinking, spot patterns, and avoid putting too much faith in a single story.

Use the Simply Wall Street Screener to quickly surface focused sets of companies that match what you are looking for, then compare them against your own criteria.

• Target potential bargains by reviewing companies that combine quality fundamentals with room for the market to catch up using the 56 high quality undervalued stocks.
• Prioritise resilience by scanning for companies with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (42 results).
• Hunt for future standouts by looking across a screener containing 24 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.